Literature DB >> 17680013

Decision for reconstructive interventions of the upper limb in individuals with tetraplegia: the effect of treatment characteristics.

G J Snoek1, J A van Til, P F M Krabbe, M J Ijzerman.   

Abstract

STUDY
DESIGN: Survey.
OBJECTIVE: To determine the effect of treatment characteristics on the decision for reconstructive interventions for the upper extremities (UE) in subjects with tetraplegia.
SETTING: Seven specialized spinal cord injury centres in the Netherlands.
METHOD: Treatment characteristics for UE reconstructive interventions were determined. Conjoint analysis (CA) was used to determine the contribution and the relative importance of the treatment characteristics on the decision for therapy. Therefore, a number of different treatment scenarios using these characteristics were established. Different pairs of scenarios were presented to subjects who were asked to choose the preferred scenario of each set.
RESULTS: Forty-nine subjects with tetraplegia with a stable C5, C6 or C7 lesion were selected. All treatment characteristics significantly influenced the choice for treatment. Relative importance of treatment characteristics were intervention type (surgery or surgery with functional electrical stimulation implant) 13%, number of operations 15%, in-patient rehabilitation period 22%, ambulant rehabilitation period 9%, complication rate 15%, improvement of elbow function 10%, improvement of hand function 15%. In deciding for therapy, 40% of the subjects focused on one characteristic.
CONCLUSION: CA is applicable in Spinal Cord Injury medicine to study the effect of health outcomes and non-health outcomes on the decision for treatment. Non-health outcomes, which relate to the intensity of treatment, are equally important or even more important than functional outcome in the decision for reconstructive UE surgery in subjects with tetraplegia.

Entities:  

Mesh:

Year:  2007        PMID: 17680013     DOI: 10.1038/sj.sc.3102110

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  7 in total

Review 1.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

2.  Comparison of two multi-criteria decision techniques for eliciting treatment preferences in people with neurological disorders.

Authors:  Maarten J Ijzerman; Janine A van Til; Govert J Snoek
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

Review 3.  Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.

Authors:  Richard De Abreu Lourenco; Marion Haas; Jane Hall; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

4.  Outcomes of reconstructive hand surgery in patients with tetraplegia and neuropathic pain.

Authors:  J Wangdell; J Fridén
Journal:  Spinal Cord       Date:  2018-06-14       Impact factor: 2.772

5.  Patient preferences for next generation neural prostheses to restore bladder function.

Authors:  P M H Sanders; M J Ijzerman; M J Roach; K J Gustafson
Journal:  Spinal Cord       Date:  2010-06-08       Impact factor: 2.772

6.  Selective neural electrical stimulation restores hand and forearm movements in individuals with complete tetraplegia.

Authors:  Wafa Tigra; Mélissa Dali; Lucie William; Charles Fattal; Anthony Gélis; Jean-Louis Divoux; Bertrand Coulet; Jacques Teissier; David Guiraud; Christine Azevedo Coste
Journal:  J Neuroeng Rehabil       Date:  2020-05-19       Impact factor: 4.262

7.  Activating effective functional hand movements in individuals with complete tetraplegia through neural stimulation.

Authors:  Christine Azevedo Coste; Lucie William; Lucas Fonseca; Arthur Hiairrassary; David Andreu; Antoine Geffrier; Jacques Teissier; Charles Fattal; David Guiraud
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.